Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix

Human Reproduction

Volumn 12, Issue 9, 1997, Pages 2028-2035

  Gonzalez Barcena, David ^a   Alvarez, Raquel Bañuelos ^a   Ochoa, Elizabeth Pere ^a   Cornejo, Imelda Cardenas ^a   Comaru Schally, Ana M ^b   Schally, Andrew S ^b   Engel, Juergen ^c   Reissmann, Thomas ^c   Riethmüller Winzen, Hilde ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ASTA MEDICA AG   (Germany)

Author keywords

Cetrorelix; Hysterectomy; LH RH antagonist; Uterine leiomyomas

Indexed keywords

CETRORELIX; ESTRADIOL; FOLLITROPIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYSTERECTOMY; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; ORGAN SIZE; PREGNANCY; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS; UTERUS MYOMA;

EID: 0030730449     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/12.9.2028     Document Type: Article

References (46)

1. Ayala, R.A., Meza, E., Cervera, A.R. et al. (1995) Effect of insulfated nafarelin (D-Nal-6-GnRH) upon uterine leiomyomata. Arch. Med. Res., 26, 523-526.
2. Bajusz, S., Csernus, V.J., Janaky, T. et al. (1988). New antagonists of LHRH: II. Inhibition and potentiation of LH-RH by closely related analogues. Int. J. Pept. Protein Res., 32, 425-435.
3. Behre, H.M., Klein. B., Steinmeyer, E. et al. (1992) Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J. Clin. Endocrinol. Metab., 75, 393-398.
4. Buttram, V.C. Jr. and Reiter, R.C. (1981) Uterine leiomyomata: etiology, symptomatology and management. Fertil. Steril., 36, 433-435.
5. Coddington, Ch.C., Collins, R.L., Shawker, T.H. et al. (1986) CA: Longacting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertil. Steril., 45, 624-629.
6. Cramer, S.F., Robertson, A.L. Jr, Ziats, N.P. et al. (1985) Growth potential of human uterine leiomyomas: some in vitro observations and their implications. Obstet. Gynecol., 66, 36-41.
7. Emons, G. and Schally. A.V. (1994) The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum. Reprod., 7, 1364-1379.
8. Filicori, M., Hall, D.A., Loughlin, J.S. et al. (1983) A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am. J. Obstet. Gynecol., 147, 726-727.
9. Friedman, A.J., Harri son-Atlas, D., Barbieri, R.L. et al. (1989) A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil. Steril., 51, 251-256.
10. Friedman, A.J., Lobel. M.S., Rein. M.S. et al. (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonist: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol., 163, 1114-1119.
11. Friedman, A.J., Hoffman, I.D., Comité, F. et al. (1991) Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebocontrolled, multicenter study. Obstet. Gynecol., 77, 720-725.
12. George, M., Lhomme, C., Lefort, J.K. et al. (1989) Long term use of an LHRH agonist in the management of uterine leiomyomas. A study of 17 cases. Int. J. Fertil., 34, 19-24.
13. González-Bárcena, D., Kastin, A.J., Coy, D.H. et al. (1977) Suppression of gonadotropin release in man by an inhibitory analogue of luteinizing hormone-re leasing hormone. Lancet, 2, 997-998.
14. Gonzalez-Barcena, D., Vadillo, B.M., García, P.E. et al. (1994a) Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormonereleasing hormone, Cetrorelix (SB-75). Eur. J Endocrinol., 131, 286-392.
15. González-Bárcena, D., Vadillo. B.M., Gómez, O.F. et al. (1994b) Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostate cancer. Prostate, 24, 84-92.
16. González-Bárcena, D., Vadillo, B.M., Cortez, M.A. et al. (1995) Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology, 45, 275-281.
17. Graves, E.J. (1992) National Hospital Discharge Survey: Annual Summary 1990. National Center for Health Statistics, Vital and Health Statistics, series 13, no. 112. Public Health Service, Hyattsville, Maryland.
18. Halmos, G., Schally, A.V. and Pinski, J. (1996) Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA, 93, 2398-2402.
19. Healy, D.L., Fraser, H.M. and Lawson, S.L. (1984) Shrinkage of a uterine fibroid after a subcutaneous infusion of LH-RH agonist. Br. Med. J., 289, 1267-1268.
20. Imai, A., Ohno, T., Iida, K. et al. (1994a) Gonadotropin-releasing hormone receptor in gynecologic tumors. Cancer, 74, 2555-2561.
21. Imai, A., Ohno, T., Iida, K. et al. (1994b) Presence of gonadotropinreleasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol. Oncol., 55, 144-148.
22. Kettel, L.M., Murphy, A.A., Morales, A.J. et al. (1993) Rapid regression of uterine leiomyomas in reponse to daily administration of gonadotropinreleasing hormone antagonist. Fertil. Steril., 60, 642-646.
23. Klingmuller, D., Schepke, M., Enzweiler, C. et al. (1993) Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol., 128, 15-18.
24. Lemay, A., Surrey, E.S. and Friedman, A.J. (1994) Extending the use of gonadotropin-releasing hormone agonists: the emerging role of steroidal and nonsteroidal agents. Fertil. Steril., 61, 21-34.
25. Letterie, G.S., Coddington, C.C., Winkel, C.A. et al. (1989) Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil. Steril., 51, 951-956.
26. Lumsden, M.A., West, C.P and Baird. D.T. (1987) Goserelin therapy before surgery for uterine fibroids. Lancet, i, 36-37.
27. Neves-e-Castro, M. and Correia, M.F. (1987) Use of luteinizing hormonereleasing hormone analogs in non-neoplastic gynecologic conditions. Semin. Reprod. Endocrinol., 5, 411-419.
28. Olivennes, F., Fanchin, R., Bouchard, P. et al. (1994) The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil. Steril., 62, 468-476.
29. Perl, V., Marquez, J., Schally, A.V. et al. (1987) Treatment of leiomyomate uteri with D-Trp6-luteinizing hormone-releasing hormone. Fertil. Steril., 48, 383-388.
30. Pinski, J. Yano, T, Szepeshazi, K. et al. (1993) Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist Cetrorelix (SB-75). J. Androi., 14, 164-169.
31. Pinski, J., Lamharzi, N., Halmos, G.et al. (I996) Chronic administration of the luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LH-RH receptor messenger ribonucleic acid levels in rats. Endocrinology, 137, 3430-3436.
32. Redding, T.W., Schally, A.V., Radulovic, S. et al. (1982) Sustained release formulations of LH-RH antagonists SB-75 inhibit proliferation and enhance the apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res., 52, 2538-2544.
33. Rein, M.S., Friedman, A.J., Stuart, J.M. et al. (1990) Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil. Steril., 53, 1018-1023.
34. Reissmann, T., Engel, J., Kutscher, B. et al. (1994) Cetrorelix. Drugs of the Future, 19, 228-237.
35. Reissmann, T., Felberbaum, R., Diedrich, K. et al. (1995) Development and applications of LHRH antagonists in the treatment of infertility. Hum. Reprod., 10, 1974-1981.
36. Reissmann, T., Kienner, T., Deger, W. et al. (1996) Pharmacological studies with Cetrorelix (SB-75), a potent antagonist of luteinizing hormone-releasing hormone. Eur. J. Cancer, 32, 1574-1579.
37. Santoro, N., Brown, J.R., Adel, T. et al. (1996) Characterization of reproductive hormonal dynamics in the perimenopause. J. Clin. Endocrinol. Metab., 81, 1495-1501.
38. Schally, A.V. (1989) The use of LH-RH analogs in gynecology and tumor therapy. In Beifort, P., Pinotti, J.A. and Eskes, T.K.A.B. (eds), Advances in Gynecology and Obstetrics. General Gynecology. Parthenon, Carnforth, UK, vol. 6, pp. 3-20.
39. Schally, A.V., Comaru-Schally, A.M. and Hollander, V. (1993) Hypothalamic and other peptide hormones. In Holland, J.F., Frei, E., Bast, R.C. et al. (eds), Cancer Medicine. Lea & Febiger, Philadelphia, pp. 827-840.
40. Schally, A.V., Halmos, G. and Pinski, J. (1995) Terminology for luteinizing hormone-releasing hormone antagonists. Fertil. Steril., 64, 226.
41. Szende, B., Srkalovic, G., Groot, K., et al. (1990) Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-re le as ing hormone antagonists SB-75. J. Natl. Cancer Inst., 82, 513-517.
42. Tamaya, T., Fujimoto, J. and Okada, H. (1985) Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet. Gynecol. Scand., 64, 307-309.
43. van Leusden, H.A.I.M. and Dogterom, A.A. (1988) Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH. Gynecol. Endocrinol., 2, 45-51.
44. Wilcox, L.S., Koonin, L.M., Pokras, R. et al. (1994) Hysterectomy in the United States, 1988-1990. Obstet. Gynecol., 83, 549-555.
45. Wiznitzer, A., Marbach, M., Hazum, E. et al. (1988) Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem. Biophys. Res. Commun., 152, 1326-1331.
46. Yano, T., Pinski. J., Halmos, G. et al. (1994) Inhibition of growth of OV1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl. Acad. Sci. USA, 91, 7090-7094.